A Phase 2 interventional study of Gecacitinib and Luspatercept in Myelofibrosis, sponsored by Peking Union Medical College Hospital. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Peking Union Medical College Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing jaktinib in Primary Myelofibrosis — 4 open to participants now, 4 under way, none of them phase 3. jaktinib · Primary Myelofibrosis.
Among the 10 studies testing jaktinib in Primary Myelofibrosis, this one is the 7th largest by planned enrollment, is one of 3 that started in 2026, is one of 4 in phase 2, and was the 10th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →4 of the 10 studies testing jaktinib in Primary Myelofibrosis are open now, in 2 countries. Recruiting first, the newest first:
Ruijin Hospital · Sites in China
Ages 18+
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Sites in United States
Ages 18+
Nanfang Hospital, Southern Medical University
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 1
First in 2019; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 31 is below the median of 43 across 490 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 37 across the 10 interventional studies. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 4 most frequent:
Peking Union Medical College Hospital is the lead sponsor of 1,156 studies on the registry; 476 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Peking Union Medical College Hospital has 1 study filed under Primary Myelofibrosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing jaktinib in Primary Myelofibrosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-center, prospective, single-arm study aims to evaluate the efficacy and safety of gecacitinib combined with luspatercept in patients with myelofibrosis and anemia who have not previously received a Janus kinase inhibitor. Participants will receive oral gecacitinib and subcutaneous luspatercept.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other serious conditions that, in the investigator's judgment, may affect participant safety or compliance, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
gecacitinib 100 mg orally twice daily, combined with luspatercept at an initial dose of 1.0 mg/kg subcutaneously every 3 weeks
Drug: Gecacitinib · Drug: Luspatercept
Gecacitinib will be administered orally at 100 mg twice daily in the fasting state. Dose adjustments will be based primarily on platelet counts and absolute neutrophil counts. Gecacitinib will be interrupted if the platelet count falls below 50 × 10\^9/L and may be resumed when the platelet count recovers to at least 50 × 10\^9/L.
Luspatercept will be administered by subcutaneous injection at an initial dose of 1.0 mg/kg every 3 weeks. The dose may be adjusted according to blood counts, up to a maximum of 1.75 mg/kg. Treatment may be interrupted if the predose hemoglobin level is at least 120 g/L or if hemoglobin increases rapidly by more than 20 g/L.
Percentage of Participants Achieving an Anemia Response
Anemia response is defined as conversion from red blood cell transfusion dependence at baseline to transfusion independence, or an increase in hemoglobin of at least 20 g/L in participants who do not require red blood cell transfusions and have a baseline hemoglobin level of 100 g/L or lower.
Time frame: 24 week
Percentage of Participants With a Sustained Increase in Mean Hemoglobin of at Least 1.0 g/dL Without Transfusion
Percentage of participants achieving an increase in mean hemoglobin of at least 1.0 g/dL from baseline for at least 12 consecutive weeks without red blood cell transfusions.
Time frame: 24 week
Time to Anemia Response
Time from the first dose of study treatment to the first documented anemia response.
Time frame: week 24
Duration of Anemia Response
The longest continuous duration of anemia response among participants who achieve an anemia response.
Time frame: week 24
Change From Baseline in Red Blood Cell Transfusion Amount and Frequency
Changes from baseline in the amount and frequency of red blood cell transfusions during study treatment.
Time frame: week 24
Change From Baseline in Hemoglobin
Change in hemoglobin concentration, measured in g/L, from baseline at scheduled treatment-period visits.
Time frame: weeks 4, 8, 12, 16, 20, and 24
SVR35
Percentage of participants achieving a reduction in spleen volume of at least 35% from baseline.
Time frame: week 12 and 24
DoMSR
Time from the first documented reduction in spleen volume of more than 35% from baseline to the first subsequent assessment showing a reduction of less than 35% from baseline.
Time frame: week 24
MPN-SAF TSS
Percentage of participants achieving a reduction of at least 50% from baseline in the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS).
Time frame: weeks 4, 8, 12, 16, 20, and 24
Reduction in Fatigue Score
Percentage of participants achieving a reduction of at least 50% from baseline in fatigue symptom score.
Time frame: week 24
Adverse Events
Incidence and severity of adverse events, including events that develop or worsen during treatment and events occurring after treatment that are considered related to the study drugs by the investigator. Serious adverse events and adverse events leading to treatment interruption or discontinuation will also be recorded.
Time frame: From the first dose through 28 days after the last dose.
PFS
Time from the first dose of study treatment to disease progression or death from any cause, whichever occurs first.
Time frame: 12 month
OS
Time from the first dose of study treatment to death from any cause.
Time frame: 12 month
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.
Of 68 non-industry phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 119. This study's planned 25 months is below that.
Counting every sponsor, half of 98 studies reached it within 66 months; a quarter within 32 and three quarters within 111.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Jaktinib
Peking Union Medical College Hospital →